AstraZeneca announced on Tuesday that it will buy China’s Gracell Biotechnologies for $1.2 billion, bringing the British drugmaker’s ambitions in the field of cell therapies to fruition. The cash deal aims to increase the value of AstraZeneca’s US-listed Gracell portfolio to $2 per ordinary share.